Another bionewbie question: Just how often during
a disease process does a lab need to get tissue
samples--say from cancer patients? Take RPR's Gencell
/Introgen p53 gene therapy trial for instance (I
assume you are still involved with that). My guess
is that to build a useful gene expression database
you would need samples of tumor at every stage
of treatment--the molecular movie idea. It seems
like this would be incredibly difficult, not only
as far as all the lab work...but for the patients as
well (sorry, a very unpleasant question, but are tumors
continually, er, sampled?) Otherwise you would end up
with a very choppy 'movie', just a few frames: Flash--
cancer inhibiting genes on, flash--they're off.
Is my conceptualization too primitive to really get
a hold on what you fellas do? I have this sci-fi image
of what gene expression databases look like--moving 3D
topographic maps, maybe it was your own website that
implanted that in my noggin, can't seem to shake the image.
__________
Thread: I'm happy to say I was able to take
some trading profits in my wife's account
today, and re-established for her a basic
(non-trading) position in GLGC, it's not
much, just that core 1000 shares, but it's
a start. I don't really have any serious
reservations about owning the stock--the
Bancboston report suggests that GLGC will
come close to breaking even next year, and that
would certainly be a great accomplishment--
a trick many small biotechs haven't learned.
The real problem is deciding where you want
to put your money now that genomics oriented
companies stocks are perking up--lately I've been
thinking about Curagen and Hyseq again, but the
fact that Steve is here on this thread is a wonderful
move by the company, and obviously has something to
do with my "first third". We need to make the best
use of his presence that we can--it is a rare exception
to the general rule for companies to ignore individual
investors. Maybe if Steve can really sell us on GLGC
I'll move up to a full position over the next few
months...
Asking the right questions is the trick--
I'll toss out a few attempts, but some help here
would be appreciated. Maybe Rick can expand on his
still unanswered question?--Flesh out what you were
getting at for those of us who are not PhD's. |
